AlphaMark Advisors’s AstraZeneca AZN Stock Holding History

AlphaMark Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$22K	Hold	171	–	–	0.01%	341
2024 Q3	$27K	Sell	171 -25	-13%	-$4.04K	0.01%	392
2024 Q2	$31K	Hold	196	–	–	0.01%	392
2024 Q1	$27K	Hold	196	–	–	0.01%	410
2023 Q4	$26K	Hold	196	–	–	0.01%	416
2023 Q3	$27K	Sell	196 -60	-23%	-$8.2K	0.01%	391
2023 Q2	$37K	Hold	256	–	–	0.02%	249
2023 Q1	$36K	Hold	256	–	–	0.02%	261
2022 Q4	$35K	Sell	256 -3	-1%	-$376	0.02%	237
2022 Q3	$28K	Hold	259	–	–	0.01%	267
2022 Q2	$34K	Hold	259	–	–	0.02%	257
2022 Q1	$34K	Hold	259	–	–	0.01%	269
2021 Q4	$30K	Buy	259 +3	+1%	+$353	0.01%	286
2021 Q3	$31K	Buy	256 +146	+133%	+$17K	0.01%	276
2021 Q2	$13K	Hold	110	–	–	﹤0.01%	372
2021 Q1	$11K	Buy	110 +50	+83%	+$5.03K	﹤0.01%	378
2020 Q4	$6K	Hold	60	–	–	﹤0.01%	404
2020 Q3	$7K	Buy	+60	New	+$6.67K	﹤0.01%	396

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

AlphaMark Advisors's AZN Position: Q4 2024 in Review

AlphaMark Advisors held its AstraZeneca (AZN) position steady in Q4 2024 at 171 shares worth $22K. The position accounts for 0.01% of the portfolio, ranked #341.

AlphaMark Advisors first reported a position in AZN in Q3 2020 and has held it in 18 quarters since. The position peaked at $37K in Q2 2023. 1,219 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

AlphaMark Advisors held 171 shares of AstraZeneca worth $22K as of Q4 2024.
AlphaMark Advisors left its AstraZeneca share count unchanged in Q4 2024.
AstraZeneca made up 0.01% of AlphaMark Advisors's portfolio in Q4 2024, its #341 holding.
AlphaMark Advisors first reported a position in AstraZeneca in Q3 2020 and has held it in 18 quarters since.
AlphaMark Advisors's AstraZeneca position peaked at $37K in Q2 2023.
1,219 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.